INT201131

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.24
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 6
Disease Relevance 0.90
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (QRFPR) signal transducer activity (QRFPR)
Anatomy Link Frequency
blood 1
QRFPR (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 42 81.48 Quite High
pruritus 12 5.00 Very Low Very Low Very Low
Bioavailability 12 5.00 Very Low Very Low Very Low
abdominal pain 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diarrhoea 18 85.44 High High
Vomiting 30 84.88 Quite High
Respiratory Tract Infection 6 83.56 Quite High
Dizziness 60 82.64 Quite High
Headache 42 81.48 Quite High
Malaria 108 68.84 Quite High
Congenital Anomalies 6 62.16 Quite High
Arrhythmias 2 Under Development 24 49.28 Quite Low
Heart Disease 6 35.28 Quite Low
Disease 12 28.84 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The greater urinary excretion of AQ-13 and CQ than their more water-soluble metabolites (Tables 4 and 5) [26] is consistent with the active transport of CQ, and possibly AQ-13, by organic cation transporters such as organic cation transporter-like 2 (ORCTL2) [46].
Localization (excretion) of AQ-13
1) Confidence 0.24 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0
In addition to the blood samples, twenty-four hour urine collections were obtained for 3 d after the 1,500/1,750 mg therapeutic dose to evaluate the urinary excretion of AQ-13, CQ, and their metabolites.
Localization (excretion) of AQ-13 in blood
2) Confidence 0.24 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0
Fisher exact test or Pearson chi-square was used to compare the frequencies of the AEs reported for AQ-13 and CQ at each dose, and between African Americans and persons of European descent.
Localization (reported) of AQ-13
3) Confidence 0.22 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0
Before the 1,500 mg therapeutic dose, 13 volunteers received a 700 mg adjustment dose of AQ-13 to compensate for the more rapid clearance of AQ-13.
Localization (clearance) of AQ-13
4) Confidence 0.22 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.14 Pain Relevance 0
The data collected in this trial also showed that both AQ-13 and CQ were absorbed into the bloodstream in a similar way, but AQ-13 was absorbed more slowly than CQ.
Localization (absorbed) of AQ-13
5) Confidence 0.22 Published 2007 Journal PLoS Clinical Trials Section Abstract Doc Link PMC1764434 Disease Relevance 0.61 Pain Relevance 0.08
Before the 1,500 mg therapeutic dose, 13 volunteers received a 700 mg adjustment dose of AQ-13 to compensate for the more rapid clearance of AQ-13.
Localization (clearance) of AQ-13
6) Confidence 0.22 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.14 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox